BioWorld1mon
Quanta Therapeutics reports new KRAS mutant inhibitors for cancer
Quanta Therapeutics Inc. has identified new pyrimidine-based GTPase KRAS G12D and G12V mutant inhibitors potentially useful for the treatment of cancer.
Business Insider1mon
Quanta Announces IND Clearance by U.S. FDA for QTX3544, an Oral G12V-Preferring Multi-KRAS Inhibitor, and Other Pipeline Updates
“With the initiation of the Phase 1 clinical trial for QTX3544 in patients with KRAS G12V-driven solid tumors, we will have three KRAS inhibitor programs in the clinic focused on the most ...
Yahoo Finance25d
Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models
SIL-204 inhibits key oncogenic KRAS mutations, including G12D, G12V, G12R, Q61H, and G13D. Intratumoral administration of SIL-204 microparticles reduced tumor cell numbers by ~3-fold, tumor area ...